COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

Completed · Not applicable

Conditions studied: SARS-CoV-2 Infection, COVID-19

In brief

SARS-CoV-2 rapid antigen over the counter clinical performance evaluation.

Key facts

Study ID

NCT05555030

Run by

New Day Diagnostics

People needed

100

Starts

2022-08-04

Expected to finish

2022-12-20

Last updated by the study team

2023-02-15

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Lay subjects greater than 2 years old that do not know their current COVID-19 status and can complete the consent/assent process in both written and spoken English may be included in the study.

You may not qualify if…

• Subjects less than 2 years old will be excluded.
• Participants that are or were medial and/or laboratory professionals will be excluded.
• Participants that cannot read and understand English will be excluded.
• High risk individuals will not be excluded unless they are too young or have prior training or experience that would exclude them.
• Participants who refuse to sign the informed consent/assent form(s) will be excluded.

Where it is running

• Paragon — Anaheim, California, United States
• EDP Biotech — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.